{"entity":{"id":"paper-arrow-pralsetinib-gainor-lancet-oncol-2021","kind":"paper","name":"ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer","aka":[],"tldr":"Pralsetinib, a second selective RET inhibitor, shrank tumours in 61 percent of previously treated and 70 percent of untreated patients with RET fusion-positive lung cancer, giving an alternative to selpercatinib.","summary":"Phase 1/2 study including 233 patients with RET fusion-positive non-small-cell lung cancer treated with pralsetinib 400 mg daily.\n\nObjective response was 61 percent in patients previously treated with platinum chemotherapy and 70 percent in treatment-naive patients, with median duration of response not reached in the latter; neutropenia, hypertension and liver enzyme rise were common.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2021","url":"https://doi.org/10.1016/S1470-2045(21)00247-3"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34118197/"}],"tags":[],"related":[],"cancers":["ret-fusion-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pralsetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00247-3","pmid":"34118197","authors":"Gainor JF, Curigliano G, Kim DW, et al.","paperType":"observational","findings":["Objective response 61 percent (previously treated) and 70 percent (treatment-naive).","Grade 3 or worse neutropenia in about 18 percent."],"whatItMeans":"Pralsetinib is approved for RET fusion-positive lung cancer and is used where selpercatinib is unavailable or not tolerated.","caveats":["Single-arm; pneumonitis and haematological toxicity more frequent than with selpercatinib in cross-trial comparison."],"changedPractice":true,"participants":233},"route":"/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/","neighbours":{"cancer":[{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"}],"drug":[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}